Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.

Dietel M, Jöhrens K, Laffert M, Hummel M, Bläker H, Müller BM, Lehmann A, Denkert C, Heppner FL, Koch A, Sers C, Anagnostopoulos I.

Cancer Gene Ther. 2013 Apr;20(4):211-21. doi: 10.1038/cgt.2013.13. Epub 2013 Mar 15. Review.

PMID:
23492822
2.

Molecular Pathology: A Requirement for Precision Medicine in Cancer.

Dietel M.

Oncol Res Treat. 2016;39(12):804-810. Epub 2016 Nov 25. Review.

3.

A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.

Dietel M, Jöhrens K, Laffert MV, Hummel M, Bläker H, Pfitzner BM, Lehmann A, Denkert C, Darb-Esfahani S, Lenze D, Heppner FL, Koch A, Sers C, Klauschen F, Anagnostopoulos I.

Cancer Gene Ther. 2015 Sep;22(9):417-30. doi: 10.1038/cgt.2015.39. Epub 2015 Sep 11. Review.

PMID:
26358176
4.

Molecular diagnostics and personalized medicine in oncology: challenges and opportunities.

Normanno N, Rachiglio AM, Roma C, Fenizia F, Esposito C, Pasquale R, La Porta ML, Iannaccone A, Micheli F, Santangelo M, Bergantino F, Costantini S, De Luca A.

J Cell Biochem. 2013 Mar;114(3):514-24. doi: 10.1002/jcb.24401.

PMID:
22991232
5.

Making the most of pathological specimens: molecular diagnosis in formalin-fixed, paraffin embedded tissue.

Fairley JA, Gilmour K, Walsh K.

Curr Drug Targets. 2012 Nov;13(12):1475-87. Review.

PMID:
22974391
6.

Human tissue in systems medicine.

Caie PD, Schuur K, Oniscu A, Mullen P, Reynolds PA, Harrison DJ.

FEBS J. 2013 Dec;280(23):5949-56. doi: 10.1111/febs.12550. Epub 2013 Oct 29. Review.

7.

Changing pathology with changing drugs: tumors of the gastrointestinal tract.

Cervera P, Fléjou JF.

Pathobiology. 2011;78(2):76-89. doi: 10.1159/000315535. Epub 2011 Jun 15. Review.

8.

[Response predictive biomarkers to targeted therapies in oncology].

Harlé A, Merlin JL.

Ann Biol Clin (Paris). 2013 Nov;71:89-97. doi: 10.1684/abc.2013.0906. Review. French.

PMID:
24235332
9.

Personalized oncology: recent advances and future challenges.

Kalia M.

Metabolism. 2013 Jan;62 Suppl 1:S11-4. doi: 10.1016/j.metabol.2012.08.016. Epub 2012 Sep 19. Review.

PMID:
22999010
10.

Personalized medicine and development of targeted therapies: The upcoming challenge for diagnostic molecular pathology. A review.

Dietel M, Sers C.

Virchows Arch. 2006 Jun;448(6):744-55. Epub 2006 Apr 22. Review.

PMID:
16736190
11.

The role of molecular diagnostics in cancer diagnosis and treatment.

Ozretić L, Heukamp LC, Odenthal M, Buettner R.

Onkologie. 2012;35 Suppl 1:8-12. doi: 10.1159/000334823. Epub 2012 Jan 20.

12.

Digital pathology in personalized cancer therapy.

Słodkowska J, García-Rojo M.

Stud Health Technol Inform. 2012;179:143-54. Review.

PMID:
22925795
13.

[The role of pathology in the predictive oncology of solid tumours].

Fabian P.

Cas Lek Cesk. 2010;149(10):462-3. Review. Czech.

PMID:
21121134
14.

Tissue sampling in lung cancer: a review in light of the MERIT experience.

Reck M, Hermes A, Tan EH, Felip E, Klughammer B, Baselga J.

Lung Cancer. 2011 Oct;74(1):1-6. doi: 10.1016/j.lungcan.2011.05.002. Epub 2011 Jun 11. Review.

PMID:
21658788
15.

Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR mutation detection in clinical formalin fixed paraffin embedded samples.

Didelot A, Le Corre D, Luscan A, Cazes A, Pallier K, Emile JF, Laurent-Puig P, Blons H.

Exp Mol Pathol. 2012 Jun;92(3):275-80. doi: 10.1016/j.yexmp.2012.03.001. Epub 2012 Mar 7.

PMID:
22426079
16.

Detection of Chromosomal Abnormalities with Different In Situ Hybridisation Techniques--the Usefulness in the Qualification of Cancer Patients for Molecularly-Targeted Therapies.

Nicoś M, Wojas-Krawczyk K, Krawczyk P, Milanowski J.

Adv Clin Exp Med. 2015 Jul-Aug;24(4):715-23. doi: 10.17219/acem/28825.

17.

[Possibilities and limitations of stratified medicine based on biomarkers and targeted therapies in oncology].

Ludwig WD.

Z Evid Fortbild Qual Gesundhwes. 2012;106(1):11-22. doi: 10.1016/j.zefq.2011.12.001. Epub 2012 Jan 10. Review. German.

PMID:
22325103
18.

High-resolution melting analysis as a sensitive prescreening diagnostic tool to detect KRAS , BRAF , PIK3CA , and AKT1 mutations in formalin-fixed, paraffin-embedded tissues.

Ney JT, Froehner S, Roesler A, Buettner R, Merkelbach-Bruse S.

Arch Pathol Lab Med. 2012 Sep;136(9):983-92. doi: 10.5858/arpa.2011-0176-OA.

PMID:
22938585
19.

Targeted therapies of solid cancers: new options, new challenges.

Awada A, Aftimos PG.

Curr Opin Oncol. 2013 May;25(3):296-304. doi: 10.1097/CCO.0b013e32835ff318. Review.

PMID:
23493191
20.

Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody.

Capper D, Preusser M, Habel A, Sahm F, Ackermann U, Schindler G, Pusch S, Mechtersheimer G, Zentgraf H, von Deimling A.

Acta Neuropathol. 2011 Jul;122(1):11-9. doi: 10.1007/s00401-011-0841-z. Epub 2011 Jun 3.

PMID:
21638088

Supplemental Content

Support Center